IN VIVO asked several leading medical device venture investors for their views on the impact of Johnson & Johnson 's acquisition of Guidant Corp. on the device dealmaking landscape, with a specific focus on opportunities for start-ups [See Deal]. (See "Elephant Cha-Cha: The J&J/Guidant Deal," IN VIVO, January 2005 Also see "Elephant Cha-Cha: The J&J/Guidant Deal" - In Vivo, 1 January, 2005..) Following are their perspectives:
Olav Bergheim, Domain Ventures:
Welcome to In Vivo
Create an account to read this article
Already a subscriber?